Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Galenea Corp. - Product Pipeline Review - 2012 - New Study Released


Print article Print article
2013-01-28 05:01:50 - Recently published research from Global Markets Direct, "Galenea Corp. - Product Pipeline Review - 2012", is now available at Fast Market Research

Global Market Direct's pharmaceuticals report, "Galenea Corp. - Product Pipeline Review - 2012" provides data on the Galenea Corp.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Galenea Corp.'s corporate website, SEC filings, investor presentations and featured press releases, both from Galenea Corp. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

* Galenea Corp. - Brief Galenea Corp. overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of Galenea Corp. human therapeutic division.
* Overview of

pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Galenea Corp. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Galenea Corp.'s pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.


Full Report Details at
- www.fastmr.com/prod/530065_galenea_corp_product_pipeline_review_ ..


Reasons to buy

* Evaluate Galenea Corp.'s strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Galenea Corp. in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Galenea Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Galenea Corp..
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Galenea Corp. and identify potential opportunities in those areas.

Report Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Galenea Corp. Snapshot
Galenea Corp. Overview
Key Information
Key Facts
Galenea Corp. - Research and Development Overview
Key Therapeutic Areas
Galenea Corp. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Galenea Corp. - Pipeline Products Glance
Galenea Corp. - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Galenea Corp. - Drug Profiles
5-HT6 Antagonist Program
Product Description
Mechanism of Action
R&D Progress
Drug For Obesity
Product Description
Mechanism of Action
R&D Progress
Drug For Schizophrenia
Product Description
Mechanism of Action
R&D Progress
Galenea Corp. - Pipeline Products By Mechanism of Action
Galenea Corp. - Recent Pipeline Updates
Galenea Corp. - Locations And Subsidiaries
Head Office
Financial Deals Landscape
Galenea Corp., Deals Summary
Galenea Corp., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Galenea Enters Into Agreement With Eisai To Develop Synaptic Modulators for Neurodegenerative Diseases
Galenea Enters Into Co-Development Agreement With Stanley Medical Research Institute
Licensing Agreements
Galenea Extends Licensing Agreement With Otsuka Pharma
Galenea Enters Into Licensing Agreement With Organix
Galenea Extends Licensing Agreement With Otsuka Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Galenea Corp., Key Information
Galenea Corp., Key Facts
Galenea Corp. - Pipeline by Indication, 2012
Galenea Corp. - Pipeline by Stage of Development, 2012
Galenea Corp. - Monotherapy Products in Pipeline, 2012
Galenea Corp. - Pre-Clinical, 2012
Galenea Corp. - Pipeline Products By Mechanism of Action, 2012
Galenea Corp. - Recent Pipeline Updates, 2012
Galenea Corp., Deals Summary
Galenea Enters Into Agreement With Eisai To Develop Synaptic Modulators for Neurodegenerative Diseases
Galenea Enters Into Co-Development Agreement With Stanley Medical Research Institute
Galenea Extends Licensing Agreement With Otsuka Pharma
Galenea Enters Into Licensing Agreement With Organix
Galenea Extends Licensing Agreement With Otsuka Pharma

List of Figures
Galenea Corp. - Pipeline by Indication, 2012
Galenea Corp. - Pipeline by Stage of Development, 2012
Galenea Corp. - Monotherapy Products in Pipeline, 2012
Galenea Corp. - Pipeline Products By Mechanism of Action, 2012

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com